235 related articles for article (PubMed ID: 26281300)
1. [Molecular biological properties of the Epstein-Barr virus LMP1 gene: structure, function and polymorphism].
Smirnova KV; Diduk SV; Senyuta NB; Gurtsevitch VE
Vopr Virusol; 2015; 60(3):5-13. PubMed ID: 26281300
[TBL] [Abstract][Full Text] [Related]
2. [Epstein-Barr Virus LMP1 oncogene variants in cell lines of different origin].
Yakovleva LS; Senyuta NB; Goncharova EV; Scherback LN; Smirnova RV; Pavlish OA; Gurtsevitch VE
Mol Biol (Mosk); 2015; 49(5):800-10. PubMed ID: 26510598
[TBL] [Abstract][Full Text] [Related]
3. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
4. Mouse model for acute Epstein-Barr virus infection.
Wirtz T; Weber T; Kracker S; Sommermann T; Rajewsky K; Yasuda T
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):13821-13826. PubMed ID: 27856754
[TBL] [Abstract][Full Text] [Related]
5. Novel roles and therapeutic targets of Epstein-Barr virus-encoded latent membrane protein 1-induced oncogenesis in nasopharyngeal carcinoma.
Tao Y; Shi Y; Jia J; Jiang Y; Yang L; Cao Y
Expert Rev Mol Med; 2015 Aug; 17():e15. PubMed ID: 26282825
[TBL] [Abstract][Full Text] [Related]
6. c-Myc Represses Transcription of Epstein-Barr Virus Latent Membrane Protein 1 Early after Primary B Cell Infection.
Price AM; Messinger JE; Luftig MA
J Virol; 2018 Jan; 92(2):. PubMed ID: 29118124
[TBL] [Abstract][Full Text] [Related]
7. LMP1-Induced Sumoylation Influences the Maintenance of Epstein-Barr Virus Latency through KAP1.
Bentz GL; Moss CR; Whitehurst CB; Moody CA; Pagano JS
J Virol; 2015 Aug; 89(15):7465-77. PubMed ID: 25948750
[TBL] [Abstract][Full Text] [Related]
8. The danger molecule HMGB1 cooperates with the NLRP3 inflammasome to sustain expression of the EBV lytic switch protein in Burkitt lymphoma cells.
Reinhart NM; Akinyemi IA; Frey TR; Xu H; Agudelo C; Brathwaite J; Burton EM; Burgula S; McIntosh MT; Bhaduri-McIntosh S
Virology; 2022 Jan; 566():136-142. PubMed ID: 34922257
[TBL] [Abstract][Full Text] [Related]
9. Expression of the Epstein-Barr virus protein LMP1 mediates tumor regression in vivo.
Cherney BW; Sgadari C; Kanegane C; Wang F; Tosato G
Blood; 1998 Apr; 91(7):2491-500. PubMed ID: 9516150
[TBL] [Abstract][Full Text] [Related]
10. LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.
Ma SD; Xu X; Plowshay J; Ranheim EA; Burlingham WJ; Jensen JL; Asimakopoulos F; Tang W; Gulley ML; Cesarman E; Gumperz JE; Kenney SC
J Clin Invest; 2015 Jan; 125(1):304-15. PubMed ID: 25485679
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt's lymphoma cells depending on viral latency program.
De Leo A; Arena G; Stecca C; Raciti M; Mattia E
Mol Cancer Res; 2011 Oct; 9(10):1346-55. PubMed ID: 21856773
[TBL] [Abstract][Full Text] [Related]
12. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
Bristol JA; Nelson SE; Ohashi M; Casco A; Hayes M; Ranheim EA; Pawelski AS; Singh DR; Hodson DJ; Johannsen EC; Kenney SC
PLoS Pathog; 2024 Apr; 20(4):e1012132. PubMed ID: 38620028
[TBL] [Abstract][Full Text] [Related]
13. The Latent Membrane Protein 1 (LMP1).
Kieser A; Sterz KR
Curr Top Microbiol Immunol; 2015; 391():119-49. PubMed ID: 26428373
[TBL] [Abstract][Full Text] [Related]
14. Functional analysis of the mutated Epstein-Barr virus oncoprotein LMP1(69del): implications for a new role of naturally occurring LMP1 variants.
Larcher C; Bernhard D; Schaadt E; Adler B; Ausserlechner MJ; Mitterer M; Huemer HP
Haematologica; 2003 Dec; 88(12):1324-35. PubMed ID: 14687985
[TBL] [Abstract][Full Text] [Related]
15. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by epstein-barr virus.
Dirmeier U; Neuhierl B; Kilger E; Reisbach G; Sandberg ML; Hammerschmidt W
Cancer Res; 2003 Jun; 63(11):2982-9. PubMed ID: 12782607
[TBL] [Abstract][Full Text] [Related]
16. RelB nuclear translocation mediated by C-terminal activator regions of Epstein-Barr virus-encoded latent membrane protein 1 and its effect on antigen-presenting function in B cells.
Pai S; O'Sullivan BJ; Cooper L; Thomas R; Khanna R
J Virol; 2002 Feb; 76(4):1914-21. PubMed ID: 11799186
[TBL] [Abstract][Full Text] [Related]
17. Antiviral agent cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies.
Abdulkarim B; Sabri S; Zelenika D; Deutsch E; Frascogna V; Klijanienko J; Vainchenker W; Joab I; Bourhis J
Oncogene; 2003 Apr; 22(15):2260-71. PubMed ID: 12700662
[TBL] [Abstract][Full Text] [Related]
18. Tumor Suppressor p53 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1.
Wang Q; Lingel A; Geiser V; Kwapnoski Z; Zhang L
J Virol; 2017 Oct; 91(20):. PubMed ID: 28794023
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha.
Wakisaka N; Kondo S; Yoshizaki T; Murono S; Furukawa M; Pagano JS
Mol Cell Biol; 2004 Jun; 24(12):5223-34. PubMed ID: 15169887
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus-encoded latent membrane protein 1 (LMP1) induces the expression of the cellular microRNA miR-146a.
Motsch N; Pfuhl T; Mrazek J; Barth S; Grässer FA
RNA Biol; 2007 Nov; 4(3):131-7. PubMed ID: 18347435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
